Explore

Rapid Read Rapid Read
Research Identifies SAMHD1 Depletion as a Potential Cancer Treatment Strategy

Research Identifies SAMHD1 Depletion as a Potential Cancer Treatment Strategy

Recent research has identified the selective depletion of tumor-associated SAMHD1 as a promising strategy to enhance the efficacy of chemotherapy and boost antitumor immune responses. SAMHD1, a protein linked to poor chemotherapy response, was targeted using FDA-approved small-molecule drugs. The study found that STA-9090, a drug that effectively reduces SAMHD1 expression, significantly increased the cytotoxicity of the chemotherapy agent cytarabine (ara-C) in acute myeloid leukemia (AML) cells. The research also demonstrated that higher SAMHD1 expression correlates with worse survival outcomes in various cancers, including AML and breast cancer. The study suggests that targeting SAMHD1 could improve treatment outcomes for patients with high SAMHD1-expressing tumors.
Rapid Read Rapid Read
Study Reveals Capecitabine and Immunotherapy Combination Improves Survival in Nasopharyngeal Carcinoma

Study Reveals Capecitabine and Immunotherapy Combination Improves Survival in Nasopharyngeal Carcinoma

A recent study has demonstrated that the combination of capecitabine with immunotherapy significantly improves progression-free survival (PFS) and overall survival (OS) in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). The research, conducted by the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center, highlights that adding capecitabine to immune maintenance therapy can enhance the efficacy of treatment by inducing angiogenic dormancy and boosting the immune response to tumor-associated antigens. The study found that patients receiving this combination therapy had a median PFS of 31.6 months, compared to shorter durations in other treatment regimens. The research also identified that patients with detectable EBV DNA post-treatment are at higher risk of disease progression and may benefit more from this therapy.
Rapid Read Rapid Read
New Brain Cancer Research Centre Announced at University of Nottingham

New Brain Cancer Research Centre Announced at University of Nottingham

Brain Tumour Research has announced a £2.6 million investment to establish a new research centre at the University of Nottingham, focusing on glioblastoma, the deadliest form of adult brain cancer. The centre aims to improve understanding and treatment of the disease, using advanced MRI imaging and artificial intelligence to detect tumour recurrence earlier. Maggie Cullen, whose son Josh died from glioblastoma, supports the initiative, hoping it will prevent other families from experiencing similar loss. The centre's principal investigator, Prof. Ruman Rahman, envisions a future where brain imaging can identify personalized treatments to prevent tumour recurrence.
Rapid Read Rapid Read
Bayer and OncoHost Utilize AI to Enhance Precision in Cancer Treatment Amid Rising Incidence in Younger Populations

Bayer and OncoHost Utilize AI to Enhance Precision in Cancer Treatment Amid Rising Incidence in Younger Populations

Bayer and OncoHost are leveraging artificial intelligence (AI) to advance precision medicine in oncology, particularly as cancer rates rise among younger demographics. Sai Jasti, Bayer's senior vice president and head of data science and AI, emphasizes the need for 'kinder medicines' due to the longer duration younger patients may require treatment. The approach involves using AI to analyze large, multimodal datasets, including genomics and clinical records, to identify patterns that are not easily detectable by humans. Ofer Sharon, CEO of OncoHost, notes that while AI holds promise, its integration into clinical practice is gradual due to the need for extensive validation. The focus is on improving data integration and model accuracy to enhance personalized care, although most treatments still follow traditional cohort-based guidelines.
Trendline Trendline
Innovative Clinical Trials Transform Cancer Research Landscape

Innovative Clinical Trials Transform Cancer Research Landscape

Innovative Clinical Trials Transform Cancer Research Landscape
Rapid Read Rapid Read
Marengo Therapeutics Unveils Promising Results from Breast Cancer Drug Combination Study

Marengo Therapeutics Unveils Promising Results from Breast Cancer Drug Combination Study

Marengo Therapeutics has presented initial results from its STARt-002 phase 1b/2 trial at the 2025 San Antonio Breast Cancer Symposium. The study investigates the combination of Invikafusp alfa and TRODELVY® in patients with metastatic breast cancer. Early findings indicate that the combination is well tolerated and shows biological activity across all dose levels. The trial demonstrated selective expansion of Vδ2/10 T cells and early anti-tumor activity in most patients. A recommended phase 2 dose has been established, and enrollment is ongoing for phase 2 expansion cohorts targeting metastatic triple-negative breast cancer and HR+/HER2– metastatic breast cancer.
Rapid Read Rapid Read
Organoid Research Advances in Cancer Immunotherapy Highlighted

Organoid Research Advances in Cancer Immunotherapy Highlighted

Recent advancements in organoid research are showing promise in addressing challenges in cancer immunotherapy. Organoids, which are miniaturized and simplified versions of organs, are being used to study tumor heterogeneity and immune escape mechanisms. The use of CRISPR-Cas9 gene editing in organoids allows for precise interrogation of biological pathways, providing insights into tumor mutation burden and immune microenvironments. These developments are crucial for understanding the varied responses to immunotherapy across different cancer types. The research emphasizes the need for more physiologically relevant models to predict clinical outcomes effectively.
Rapid Read Rapid Read
King Charles III Announces Potential Reduction in Cancer Treatment Schedule Amid Awareness Campaign

King Charles III Announces Potential Reduction in Cancer Treatment Schedule Amid Awareness Campaign

King Charles III has provided an update on his ongoing cancer treatment, indicating that his treatment schedule may be reduced in 2026. The British monarch, who is 77 years old, shared this news through a video message on social media platforms as part of the Stand Up to Cancer 2025 campaign. Diagnosed with an unspecified form of cancer following a procedure for an enlarged prostate, King Charles has been undergoing treatment since February 2024. Despite a brief hospitalization in March 2025 due to side effects, he resumed public duties in April 2024. In his message, King Charles emphasized the importance of early cancer diagnosis, noting that nine million people in the UK are not up to date with available screenings. He also introduced a new online National Screening checker to help individuals determine their eligibility for cancer screenings.
Rapid Read Rapid Read
King Charles Announces Reduction in Cancer Treatment Due to Positive Response

King Charles Announces Reduction in Cancer Treatment Due to Positive Response

King Charles III has announced a significant milestone in his cancer treatment, revealing that due to early diagnosis and effective intervention, his treatment schedule will be reduced in the new year. This announcement was made in a video message broadcasted on Channel 4 as part of the Stand Up To Cancer campaign. The King, who was diagnosed with cancer in February 2024, has not disclosed the specific type of cancer but has been undergoing regular outpatient treatment. According to Buckingham Palace, the King has responded exceptionally well to the treatment, allowing doctors to move his care into a precautionary phase. Despite his diagnosis, King Charles has maintained a busy schedule, including state visits and public engagements, emphasizing the importance of early cancer detection and screening programs.
Rapid Read Rapid Read
Marengo Therapeutics Reports Promising Results from Breast Cancer Drug Combination Study

Marengo Therapeutics Reports Promising Results from Breast Cancer Drug Combination Study

Marengo Therapeutics has announced initial results from its STARt-002 phase 1b/2 trial, which combines Invikafusp alfa and TRODELVY® for treating metastatic breast cancer. The study, presented at the 2025 San Antonio Breast Cancer Symposium, shows that the combination is well tolerated and biologically active. The trial focuses on patients with previously treated metastatic triple-negative breast cancer (TNBC) and HR+/HER2– metastatic breast cancer. Early findings indicate that the regimen induces robust expansion of Vβ6/10 T cells and shows early anti-tumor activity, with two confirmed partial responses. A recommended phase 2 dose has been established, and enrollment is ongoing in North America.
Rapid Read Rapid Read
King Charles Announces Reduction in Cancer Treatment Following Early Diagnosis

King Charles Announces Reduction in Cancer Treatment Following Early Diagnosis

King Charles III has announced that due to an early diagnosis and effective treatment, his cancer treatment will be scaled back in the coming year. In a recorded message broadcast on British television, the 77-year-old monarch emphasized the importance of early cancer detection, urging the public to participate in screening programs. Charles highlighted that early diagnosis has been crucial in his own treatment, allowing him to maintain an active lifestyle. The announcement marks a significant shift from the traditional privacy maintained by the British royal family regarding health matters. Charles has been open about his diagnosis since February 2024, which has reportedly led to increased public interest in cancer symptoms and treatments.
Rapid Read Rapid Read
Marengo Therapeutics Presents Promising Results from Breast Cancer Study at Symposium

Marengo Therapeutics Presents Promising Results from Breast Cancer Study at Symposium

Marengo Therapeutics presented initial results from its STARt-002 clinical trial at the 2025 San Antonio Breast Cancer Symposium. The study investigates the combination of Invikafusp alfa and TRODELVY® in patients with metastatic breast cancer. Early findings indicate that the combination is well tolerated and shows biological activity across all dose levels. The trial demonstrated selective expansion of Vβ6/10 T cells and early anti-tumor activity, with two confirmed partial responses. A recommended phase 2 dose has been established, and enrollment is ongoing for two expansion cohorts targeting triple-negative and HR+/HER2- metastatic breast cancer.